Astegolimab (MSTT 1041A, RG 6149) is a human IgG2 monoclonal antibody. Astegolimab blocks IL-33 signaling by targeting the IL-33 receptor ST2. Astegolimab reduces p53 expression, mitigates IL33-upregulated SASP factors such as IL1alpha, IL6 and MCP1. Astegolimab mitigates IL33-increased p-p65/p65 ratio. Astegolimab blocks CM-induced neutrophil extracellular trap (NET) formation. Astegolimab is used in chronic obstructive pulmonary disease (COPD) and myocardial research[1][2][3].
Molekulargewicht:
(144.98 kDa)
Reinheit:
99.00
CAS Nummer:
[2173054-79-8]
Target-Kategorie:
Interleukin Related,MDM-2/p53,NF-kappaB
Anwendungsbeschreibung:
MCE Product type: Inhibitory Antibodies
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten